HER2-low als neuer Biomarker beim Mammakarzinom?

The article offers an analysis of the benefits of HER2 targeted therapies for the prognosis of patients with HER2-positive breast cancer. It mentions those affected with low HER2 expression could also benefit from therapy with antibody-drug conjugates (ADCs). It also mentions HER2 overexpression or amplification occurs in various tumor entities, and is associated with more aggressive tumor growth and lower overall survival rates without appropriate targeted therapy.